Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth

Growth retardation is a constant feature of Noonan syndrome (NS) but its physiopathology remains poorly understood. We previously reported that hyperactive NS-causing SHP2 mutants impair the systemic production of insulin-like growth factor 1 (IGF1) through hyperactivation of the RAS/extracellular signal-regulated kinases (ERK) signalling pathway. Besides endocrine defects, a direct effect of these mutants on growth plate has not been explored, although recent studies have revealed an important physiological role for SHP2 in endochondral bone growth. We demonstrated that growth plate length was reduced in NS mice, mostly due to a shortening of the hypertrophic zone and to a lesser extent of the proliferating zone. These histological features were correlated with decreased expression of early chondrocyte differentiation markers, and with reduced alkaline phosphatase staining and activity, in NS murine primary chondrocytes. Although IGF1 treatment improved growth of NS mice, it did not fully reverse growth plate abnormalities, notably the decreased hypertrophic zone. In contrast, we documented a role of RAS/ERK hyperactivation at the growth plate level since 1) NS-causing SHP2 mutants enhance RAS/ERK activation in chondrocytes in vivo (NS mice) and in vitro (ATDC5 cells) and 2) inhibition of RAS/ERK hyperactivation by U0126 treatment alleviated growth plate abnormalities and enhanced chondrocyte differentiation. Similar effects were obtained by chronic treatment of NS mice with statins. In conclusion, we demonstrated that hyperactive NS-causing SHP2 mutants impair chondrocyte differentiation during endochondral bone growth through a local hyperactivation of the RAS/ERK signalling pathway, and that statin treatment may be a possible therapeutic approach in NS.

[1]  D. Moore,et al.  SHP2 Regulates the Osteogenic Fate of Growth Plate Hypertrophic Chondrocytes , 2017, Scientific Reports.

[2]  K. Rauen,et al.  Expansion of the RASopathies , 2016, Current Genetic Medicine Reports.

[3]  S. Murakami,et al.  ERK1 and ERK2 Regulate Chondrocyte Terminal Differentiation During Endochondral Bone Formation , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  A. Mikos,et al.  Novel applications of statins for bone regeneration. , 2015, National science review.

[5]  A. Deodati,et al.  The Impact of Growth Hormone Therapy on Adult Height in Noonan Syndrome: A Systematic Review , 2015, Hormone Research in Paediatrics.

[6]  Alcino J. Silva,et al.  Mechanism and treatment for the learning and memory deficits associated with mouse models of Noonan syndrome , 2014, Nature Neuroscience.

[7]  S. Ikegawa,et al.  Statin treatment rescues FGFR3 skeletal dysplasia phenotypes , 2014, Nature.

[8]  F. Beier,et al.  Liver X Receptor activation delays chondrocyte hypertrophy during endochondral bone growth. , 2014, Osteoarthritis and cartilage.

[9]  M. Warman,et al.  SHP2 Regulates Chondrocyte Terminal Differentiation, Growth Plate Architecture and Skeletal Cell Fates , 2014, PLoS genetics.

[10]  D. Moore,et al.  Corrigendum: Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling , 2014, Nature.

[11]  P. King,et al.  Targeted Disruption of Shp2 in Chondrocytes Leads to Metachondromatosis With Multiple Cartilaginous Protrusions , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  C. Catsman-Berrevoets,et al.  Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial , 2013, The Lancet Neurology.

[13]  P. King,et al.  Induction of SHP2 Deficiency in Chondrocytes Causes Severe Scoliosis and Kyphosis in Mice , 2013, Spine.

[14]  P. Lapinski,et al.  Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice , 2013, Disease Models & Mechanisms.

[15]  Florent Elefteriou,et al.  The ras-GTPase activity of neurofibromin restrains ERK-dependent FGFR signaling during endochondral bone formation. , 2013, Human molecular genetics.

[16]  D. Moore,et al.  Ptpn11 Deletion in A Novel Cartilage Cell Causes Metachondromatosis by Activating Hedgehog Signaling , 2013, Nature.

[17]  C. Farquharson,et al.  SOCS2 is the critical regulator of GH action in murine growth plate chondrogenesis , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  B. Neel,et al.  Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature , 2012, Proceedings of the National Academy of Sciences.

[19]  J. Seidman,et al.  Loss-of-Function Mutations in PTPN11 Cause Metachondromatosis, but Not Ollier Disease or Maffucci Syndrome , 2011, PLoS genetics.

[20]  Y. Mishina,et al.  Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations , 2011, Disease Models & Mechanisms.

[21]  A. Kawanami,et al.  Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal , 2011, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[22]  B. Gelb,et al.  Noonan syndrome and clinically related disorders. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[23]  K. Yudoh,et al.  Statin prevents chondrocyte aging and degeneration of articular cartilage in osteoarthritis (OA) , 2010, Aging.

[24]  J. Allanson,et al.  Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines , 2010, Pediatrics.

[25]  S. Lyonnet,et al.  Functional Effects of PTPN11 (SHP2) Mutations Causing LEOPARD Syndrome on Epidermal Growth Factor-Induced Phosphoinositide 3-Kinase/AKT/Glycogen Synthase Kinase 3β Signaling , 2010, Molecular and Cellular Biology.

[26]  A. Kawanami,et al.  Extracellular Signal-Regulated Kinase 1 (ERK1) and ERK2 Play Essential Roles in Osteoblast Differentiation and in Supporting Osteoclastogenesis , 2009, Molecular and Cellular Biology.

[27]  Tomoki Nakamura,et al.  Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations , 2009, Proceedings of the National Academy of Sciences.

[28]  K. Malizos,et al.  Protective effect of atorvastatin in cultured osteoarthritic chondrocytes , 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[29]  B. Neel,et al.  Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation , 2009, Proceedings of the National Academy of Sciences.

[30]  J. Molkentin,et al.  Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome , 2008, Proceedings of the National Academy of Sciences.

[31]  Samuel Arvidsson,et al.  QuantPrime – a flexible tool for reliable high-throughput primer design for quantitative PCR , 2008, BMC Bioinformatics.

[32]  Francis Berenbaum,et al.  Primary culture and phenotyping of murine chondrocytes , 2008, Nature Protocols.

[33]  Alcino J. Silva,et al.  Effect of Simvastatin on Cognitive Functioning in Children with Neurofibromatosis Type 1 a Randomized Controlled Trial , 2022 .

[34]  G. Dorn,et al.  Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. , 2007, The Journal of clinical investigation.

[35]  Alcino J. Silva,et al.  The HMG-CoA Reductase Inhibitor Lovastatin Reverses the Learning and Attention Deficits in a Mouse Model of Neurofibromatosis Type 1 , 2005, Current Biology.

[36]  M. Phillip,et al.  Endocrine Regulation of the Growth Plate , 2005, Hormone Research in Paediatrics.

[37]  N. Wittekindt,et al.  PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[38]  D. Gilliland,et al.  Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation , 2004, Nature Medicine.

[39]  S. Murakami,et al.  Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. , 2004, Genes & development.

[40]  H. Kronenberg,et al.  Developmental regulation of the growth plate , 2003, Nature.

[41]  M. Mercuri,et al.  Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial With Simvastatin , 2002, Circulation.

[42]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[43]  R. Adar,et al.  The Transmembrane Mutation G380R in Fibroblast Growth Factor Receptor 3 Uncouples Ligand-Mediated Receptor Activation from Down-Regulation , 2000, Molecular and Cellular Biology.

[44]  V. Rosen,et al.  Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage [published erratum appears in J Cell Biol 1995 Feb;128(4):following 713] , 1994, The Journal of cell biology.

[45]  S. Sebti,et al.  Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. , 1991, Cancer communications.

[46]  M. Vidaud,et al.  Noonan syndrome: relationships between genotype, growth, and growth factors. , 2006, The Journal of clinical endocrinology and metabolism.

[47]  J. Terwilliger,et al.  Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. , 2001, Developmental biology.